Baxter International (BAX - Free Report) recently completed its previously-announced acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for a deal value of $350 million. The buyout is expected to boost Baxter’s Advanced Surgery unit.
Following the release, shares of the Zacks Rank #3 (Hold) company rose 1% to $93.16 at close.
For investors’ notice, Baxter had entered a definitive agreement to acquire Seprafilm Adhesion Barrier and related assets from Sanofi last December. Notably, France-based Sanofi is a pharmaceutical company, providing healthcare solutions in more than 170 countries.
How Does Baxter Stand to Gain?
Sanofi’s Seprafilm product family is used to reduce the incidence, extent and severity of adhesions in pelvic and abdominal surgeries. With a solid presence in the United States, Japan, China, South Korea and France, this product family is likely to expand Baxter’s Advanced Surgery product portfolio.
Thus, Baxter’s hospital and surgery customers will gain access to Seprafilm products apart from the company’s flagship hemostats and sealants.
Moreover, Allied Market Research projects the global surgical equipment market to reach a worth of $15.74 billion by 2023, at a CAGR of 7%.
Hence, Baxter’s latest acquisition has been a well-timed one.
Advanced Surgery at a Glance
Baxter’s Advanced Surgery offers clinically differentiated surgical care products which treat hemostasis, tissue sealing, reconstruction, tissue repair, intraoperative patient care and inhaled anesthesia. The segment has been a significant contributor to the company’s top line.
Some of the key products in the unit are FLOSEAL Hemostatic Matrix, TISSEEL for surgical care, ACTIFUSE Bone Graft and COSEAL Surgical Sealant.
Notably, in recent times, the segment saw an 8% year-over-year rise in revenues, driven by strength in hemostats and sealants.
Reflective of these, over the past year, shares of Baxter have rallied 25.9% outperforming the industry’s 8.9% rise.
Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation (ABC - Free Report) , Cardinal Health (CAH - Free Report) and Patterson Companies (PDCO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AmerisourceBergen’s long-term earnings are expected to grow 7.4%.
Cardinal Health’s long-term earnings are projected to rise 6.2%.
Patterson long-term earnings are estimated to climb 6.4%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>